Intelligent Antibody Discovery

News

Abeome and CDC to Collaborate on Zika Antibody Discovery

Posted on April 19th, 2017

Athens, Georgia, April 19, 2017 – Abeome Corporation announced today that it has signed a Research Collaboration Agreement (RCA) with Centers for Disease Control and Prevention (CDC) for the identification of novel antibodies binding to the Zika virus using Abeome’s proprietary AbeoMouseTM platform. “We are very pleased to collaborate with the CDC using our proprietary antibody […]

Abeome to Present New Data on IL-25 Asthma Program at Keystone Asthma: From Pathway Biology to Precision Therapeutics

Posted on February 3rd, 2017

Athens, Georgia, February 3, 2017 – Abeome Corporation will present 2 posters at Keystone February 13-16, 2017 describing significant advancements in its IL-25 asthma program. For more information see: Keystone_IL25_Abeome_3026 and: Keystone_IL25_Abeome_1005

Abeome Awarded $1.5M Grant for Technology and Therapeutic Antibody Development

Posted on September 22nd, 2016

Abeome Corporation announced today that it has received notification from the National Institute of Health – National Heart, Blood and Lung Institute of an award granting $1,482,472 over two years for the further development of proprietary monoclonal antibodies in Abeome’s portfolio.

Abeome Honored by Georgia Bio for AbeoMouse™

Posted on January 22nd, 2016

Abeome Corporation announced today it has been named a Georgia Bio Innovation Award Winner.

Abeome Closes $2M Angel Round

Posted on January 5th, 2016

Abeome Corporation announced today the closing of a $2M Angel Round.

Abeome Launches New Website and Brand Refresh

Posted on July 16th, 2015

Abeome announces a new website and brand refresh.

Abeome Receives Grant for AbeoMouse™ Technology

Posted on February 10th, 2014

Abeome Corporation announced today the receipt of an award letter for a Small Business Innovative Research (SBIR) grant in the amount of $217,860 over 10 months.

Abeome Corporation Receives Grant to Study Obesity

Posted on March 15th, 2013

Abeome Corporation announced today the receipt of an award letter for a Small Business Innovative Research (SBIR) grant in the amount of $275,916 over 10 months. The grant, titled “Semi-Targeted Immunotherapeutic Approach for Treatment of Obesity,” is a Phase 1 grant focused on generating a large number of monoclonal antibodies to human preadipocytes, the cells that are the precursors to fat cells.

Abeome Receives Grant for AbeoMouse™ Technology

Posted on March 1st, 2013

Abeome has entered into a non-exclusive agreement with Enzo Life Sciences (NASDAQ: ENZO) to distribute core technology (DiSH™) and related growth media components in the form of kits to Enzo’s worldwide network of life science customers.